Myriad Genetics, Inc. (NASDAQ:MYGN) Shares Sold by Continental Advisors LLC

Continental Advisors LLC lessened its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 19.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 29,392 shares of the company’s stock after selling 7,000 shares during the period. Continental Advisors LLC’s holdings in Myriad Genetics were worth $895,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wealthcare Advisory Partners LLC acquired a new position in shares of Myriad Genetics during the 1st quarter worth about $37,000. Vantage Consulting Group Inc purchased a new stake in Myriad Genetics during the 4th quarter valued at about $25,000. Altshuler Shaham Ltd purchased a new stake in Myriad Genetics during the 1st quarter valued at about $41,000. Penserra Capital Management LLC grew its stake in Myriad Genetics by 174.3% during the 4th quarter. Penserra Capital Management LLC now owns 1,750 shares of the company’s stock valued at $34,000 after acquiring an additional 1,112 shares in the last quarter. Finally, Captrust Financial Advisors grew its stake in Myriad Genetics by 1,764.1% during the 1st quarter. Captrust Financial Advisors now owns 2,703 shares of the company’s stock valued at $82,000 after acquiring an additional 2,558 shares in the last quarter. Hedge funds and other institutional investors own 95.47% of the company’s stock.

Several analysts recently issued reports on MYGN shares. The Goldman Sachs Group started coverage on shares of Myriad Genetics in a research note on Thursday, June 3rd. They set a “sell” rating and a $25.00 price objective for the company. Raymond James started coverage on shares of Myriad Genetics in a research note on Tuesday, June 15th. They set a “market perform” rating for the company. One analyst has rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $25.33.

In related news, Director Daniel K. Spiegelman sold 3,139 shares of the stock in a transaction that occurred on Thursday, June 17th. The shares were sold at an average price of $30.52, for a total transaction of $95,802.28. Following the completion of the transaction, the director now owns 23,129 shares of the company’s stock, valued at approximately $705,897.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jerry S. Lanchbury sold 50,000 shares of the stock in a transaction that occurred on Friday, July 9th. The stock was sold at an average price of $32.62, for a total transaction of $1,631,000.00. Following the transaction, the insider now directly owns 259,255 shares of the company’s stock, valued at approximately $8,456,898.10. The disclosure for this sale can be found here. In the last three months, insiders sold 285,428 shares of company stock valued at $9,200,150. Corporate insiders own 1.70% of the company’s stock.

Shares of Myriad Genetics stock traded down $0.04 during mid-day trading on Thursday, hitting $32.03. The stock had a trading volume of 9,958 shares, compared to its average volume of 781,882. The firm’s 50-day simple moving average is $29.86. Myriad Genetics, Inc. has a 12-month low of $11.32 and a 12-month high of $34.02. The company has a current ratio of 2.21, a quick ratio of 2.04 and a debt-to-equity ratio of 0.18. The company has a market cap of $2.47 billion, a price-to-earnings ratio of -15.24 and a beta of 1.59.

Myriad Genetics (NASDAQ:MYGN) last posted its quarterly earnings results on Sunday, May 2nd. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.09. Myriad Genetics had a negative net margin of 27.26% and a negative return on equity of 7.33%. The business had revenue of $173.10 million during the quarter, compared to analysts’ expectations of $155.36 million. During the same quarter in the prior year, the company posted ($0.08) EPS. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, equities research analysts anticipate that Myriad Genetics, Inc. will post -0.64 earnings per share for the current year.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool.

Read More: What is included in the gross domestic product?

Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).

Institutional Ownership by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.